National Prociency Testing Result of CYP2D6*10 Genotyping for Adjuvant Tamoxifen Therapy in China.
Tamoxifen has been successfully used for treating breast cancer and preventing cancer recurrence. Cytochrome P450 2D6 (CYP2D6) plays a key role in the process of metabolizing tamoxifen to its active moiety, endoxifen. Patients with variants of the CYP2D6 gene may not receive the full benefit of tamo...
Main Authors: | Guigao Lin, Kuo Zhang, Lang Yi, Yanxi Han, Jiehong Xie, Jinming Li |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2016-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5015788?pdf=render |
Similar Items
-
Correction: National Prociency Testing Result of CYP2D6*10 Genotyping for Adjuvant Tamoxifen Therapy in China.
by: PLOS ONE Staff
Published: (2016-01-01) -
Implementation of Cell Samples as Controls in National Proficiency Testing for Clopidogrel Therapy-Related CYP2C19 Genotyping in China: A Novel Approach.
by: Guigao Lin, et al.
Published: (2015-01-01) -
The Impact of CYP2D6 Genotyping on Tamoxifen Treatment
by: Roberta Ferraldeschi, et al.
Published: (2010-04-01) -
Circulating unmethylated insulin DNA as a potential non-invasive biomarker of beta cell death in type 1 Diabetes: a review and future prospect
by: Kuo Zhang, et al.
Published: (2017-04-01) -
Results of the National External Quality Assessment for Toxoplasmosis Serological Testing in China.
by: Kuo Zhang, et al.
Published: (2015-01-01)